Comment développer un antidépresseur au mécanisme d’action innovant : l’exemple de l’agomélatine

Moller HJ. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand 2003 ; 418 (suppl) : 73-80.

Vida S, Looper K. Precision and comparability of adverse event rates of newer antidepressants. J Clin Psychopharmacol 1999 ; 19 : 416-26.

Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004 ; 19 : 271-80.

Manji HK, Gottesman II, Gould TD. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE 2003 ; 207 : pe49.

Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opin Investig Drugs 2001 ; 10 : 1789-96.

Griebel G, Simiand J, Steinberg R, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3- fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3- thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002 ; 301 : 333-45.

Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998 ; 281 : 1640-5.

Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999 ; 375 : 31-40.

Kempermann G, Kronenberg G. Depressed new neurons. Adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry 2003 ; 54 : 499-503.

Malberg JE, Schecter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005 ; 11 : 145-55.

Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon? Biol Psychiatry 2004 ; 56 : 146-50.

Brown R, Kocsis JH, Caroff S, et al. Differences in nocturnal melatonin secretion between melancholic depressed patients and control subjects. Am J Psychiatry 1985 ; 142 : 811-6.

Souetre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatr Res 1989 ; 28 : 263-8.

Cheeta S, Ruigt G, Van Proosdij J, Willner P. Changes in sleep architecture following chronic mild stress. Biol Psychiatry 1997 ; 41 : 419-27.

Gorka Z, Moryl E, Papp M. Effect of chronic mild stress on circadian rhythms in the locomotor activity in rats. Pharmacol Biochem Behav 1996 ; 54 : 229-34.

Sekula LK, Lucke JF, Heist EK, et al. Neuroendocrine aspects of primary endogenous depression. XV. Mathematical modeling of nocturnal melatonin secretion in major depressives and normal controls. Psychiatr Res 1997 ; 69 : 143-53.

Szymanska A, Rabe-Jablonska J, Karasek M. Diurnal profile of melatonin concentrations in patients with major depression: relationship to the clinical manifestation and antidepressant treatment. Neuroendocrinol Lett 2001 ; 22 : 192-8.

Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 1992 ; 35 : 1484-6.

Van Reeth O, Olivares E, Zhang Y, et al. Comparative effects of a melatonin agonist on the circadian system in mice and Syrian hamsters. Brain Res 1997 ; 762 : 185-94.

Pitrosky B, Kirsch R, Malan A, et al. Organization of rat circadian rhythms during daily infusion of melatonin or S20098, a melatonin agonist. Am J Physiol Regul Integr Comp Physiol 1999 ; 277 : R812-28.

Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol Biochem Behav 1996 ; 54 : 713-8.

Armstrong SM, Mac-Nulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol Biochem Behav 1993 ; 46 : 45-9.

Redman JR, Guardiola-Lemaitre B, Brown M, et al. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology(Berl) 1995 ; 118 : 385-90.

Van Reeth O, Weibel L, Olivares E, et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am J Physiol Regul Integr Comp Physiol 2001 ; 280 : R1582-91.

Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res 2000 ; 880 : 207-11.

Van Reeth O, Olivares E, Turek FW, et al. Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist. Neuroreport 1998 ; 9 : 1901-5.

Kant GJ, Bauman RA, Pastel RH, et al. Effects of controllable versus uncontrollable stress on circadian temperature rhythms. Physiol Behav 1991 ; 49 : 625-30.

Kopp C, Vogel E, Rettori MC, et al. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav Pharmacol 1999 ; 10 : 73-83.

Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003 ; 28 : 694-703.

Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatr Neurosci 2004 ; 29 : 126-33.

Bertaina-Anglade V, Mocaer E, Drieu-La-Rochelle C. Antidepressant-like action of agomelatine (S20098) in the learned helpesness test. Int J Neuropsychopharmacol 2002 ; 5 : 1.

Norman TR, Irons J, Cranston I. Effect of the novel antidepressant agomelatine in the olfactory bulbectomised rat. Int J Neuropsychopharmacol 2004 ; 7 (suppl 1) : S461.

Mitchell PJ, Redfern PH. Animal models of depressive illness: the importance of chronic drug treatment. Curr Pharm Des 2005 ; 11 : 203.

Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine(2C) receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003 ; 306 : 954-64.

Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT(2C) receptor blockade. Psychopharmacology 2005 ; 177 : 1-12.

Hanoun N, Mocaer E, Boyer PA, et al. Differential effects of the novel antidepressant agomelatine (S20098) versus fluoxetine on 5-HT(1A) receptors in the rat brain. Neuropharmacology 2004 ; 47 : 515-26.

Daszuta A, Banasr M, Hery M, Mocaer E. Agomelatine, a new antidepressant drug, increases cell proliferation in adult hippocampus. 33^rd Annual Meeting of the Society for Neuroscience, November 8-13, 2003. New-Orleans : Society for Neuroscience, 2003 : 849-3.

Morley-Fletcher S, Mairesse J, Mocaer E, et al.Chronic treatment with agomelatine increases hippocampal cell proliferation in prenatally stressed rats. 33^rd Annual Meeting of the Society for Neuroscience, November 8-13, 2003. New-Orleans : Society for Neuroscience, 2003 : 506-20.

Wiley JL, Dance ME, Balster RL. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. Psychopharmacology (Berl) 1998 ; 140 : 503-9.